Clinical Trials Logo

Benign Essential Blepharospasm clinical trials

View clinical trials related to Benign Essential Blepharospasm.

Filter by:
  • None
  • Page 1

NCT ID: NCT06195241 Not yet recruiting - Hemifacial Spasm Clinical Trials

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

Start date: July 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer: 1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response? Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

NCT ID: NCT02370875 Completed - Clinical trials for Benign Essential Blepharospasm

rTMS and Botulinum Toxin in Benign Essential Blepharospasm

Start date: February 2015
Phase: N/A
Study type: Interventional

Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therapy can be easily combined with BoNT injections to enhance the effects of BoNT in BEB.